Filip Janku Sells 6,000 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 6,000 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $22.95, for a total value of $137,700.00. Following the completion of the sale, the insider directly owned 59,992 shares in the company, valued at approximately $1,376,816.40. This represents a 9.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total transaction of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock traded up $0.30 during mid-day trading on Tuesday, hitting $24.20. The company’s stock had a trading volume of 2,334,415 shares, compared to its average volume of 1,373,686. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -16.35 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.12 and a 52-week high of $25.77. The business has a 50-day moving average price of $19.06 and a 200 day moving average price of $18.69.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Equities research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Guggenheim raised their price objective on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. raised their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.33.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GLUE. GAMMA Investing LLC purchased a new position in Monte Rosa Therapeutics during the 4th quarter valued at $30,000. Russell Investments Group Ltd. purchased a new stake in shares of Monte Rosa Therapeutics in the third quarter valued at approximately $32,000. Lazard Asset Management LLC grew its stake in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the period. Institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.